Dr. Reddy's surges on launching generic version of Sapropterin Dihydrochloride Powder for Oral Solution

Dr. Reddys Laboratories is currently trading at Rs. 4715.00, up by 97.45 points or 2.11% from its previous closing of Rs. 4617.55 on the BSE.

The scrip opened at Rs. 4643.00 and has touched a high and low of Rs. 4734.45 and Rs. 4643.00 respectively. So far 25239 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5514.65 on 21-Sep-2020 and a 52 week low of Rs. 3200.00 on 07-Apr-2020.

Last one week high and low of the scrip stood at Rs. 4734.45 and Rs. 4423.20 respectively. The current market cap of the company is Rs. 78678.78 crore.

The promoters holding in the company stood at 26.73%, while Institutions and Non-Institutions held 43.86% and 29.41% respectively.

Dr. Reddy’s Laboratories has launched Sapropterin Dihydrochloride Powder for Oral Solution, 100mg, a therapeutic equivalent generic version of Kuvan (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, approved by the U.S. Food and Drug Administration (USFDA).

Dr. Reddy’s Sapropterin Dihydrochloride Powder for Oral Solution, is available in 100 mg unit dose packets in a 30 count carton.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.